Gossamer Bio, Inc. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On August 20, 2026, Gossamer Bio, Inc. issued Series A-1, A-2, and A-3 Convertible Preferred Stock (100,000 shares authorized for Series A-3) alongside pre-funded warrants and FDA approval-contingent warrants to unnamed purchasers. The Series A-3 Preferred Stock carries a 4X liquidation preference ($4,000/share), converts at $0.187/share upon stockholder approval, and includes stringent anti-dilution, voting, and dividend protections prior to that approval. Specific dollar amounts and purchaser identities are not disclosed in this filing excerpt.
Why this rating
Complex financing structure with favorable terms to investors; stockholder approval required to convert preferred stock reduces immediate dilution. Dollar magnitude and investor composition unknown. Standard for biotech stage-financing but heavily investor-favoring.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.